Comparison of Fluconazole Renal Penetration Levels in Healthy and Candida albicans-Infected Wistar Rats

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5852-5857

  Azeredo, Francine Johansson ^a   De Araújo, Bibiana Verlindo ^a   Haas, Sandra Elisa ^a   Torres, Bruna ^a   Pigatto, Maiara ^a   De Andrade, Cristiane ^a   Costa, Teresa Dalla ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG PENETRATION; IN VITRO STUDY; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CANDIDA ALBICANS; CANDIDIASIS; FLUCONAZOLE; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; MICRODIALYSIS; PERMEABILITY; RATS; RATS, WISTAR;

EID: 84868035135     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01323-12     Document Type: Article

References (25)

1. Andes D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. 20:679-697.
2. Andes D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
3. Araujo BV, Silva CF, Haas SE, Dalla Costa T. 2008. Microdialysis as a tooltodetermine the free kidney levelsofvoriconazoleinrodents: samodel to study the technique feasibility for a moderately lipophilic drug. J. Pharm. Biomed. Anal. 47:876-881.
4. Araujo BV, Silva CF, Haas SE, Dalla Costa T. 2009. Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.infected Wistar rats. Int. J. Antimicrob. Agents 33:154-159.
5. Balk MW, Crumrine MH, Fischer GW. 1978. Evaluation of miconazole therapy in experimental disseminated candidiasis in laboratory rats. Antimicrob. Agents Chemother. 13:321-325.
6. Bustamante CI. 2005. Treatment of Candida infection: a view from the trenches! Curr. Opin. Infect. Dis. 18:490-495.
7. CCAC. 2003. Guidelines. Canadian Council on Animal Care, Ottawa, Ontario, Canada. http://ccac.ca/Documents/Standards/Guidelines/Facilities.pdf.
8. FDA. 2001. Guidance for industry - bioanalytical method validation. FDA, Washington, DC. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ UCM128049.pdf. Accessed September 2012.
9. Graybill J, Montalbo E, Patterson T. 1998. Fluconazole versus Candida albicans: a complex relationship. Antimicrob. Agents Chemother. 42: 2938-2942.
10. Humphrey MJ, Jevons S, Tarbit SH. 1985. Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents and Chemother. 28:648-653.
11. Joukhadar C, Derendorf H, Muller M. 2001. Microdialysis - a novel tool for clinical studies of anti-infective agents. Eur. J. Clin. Pharmacol. 57:211-219.
12. Kim SS, et al. 2007. An optimized analytical method of fluconazole in human plasma by high-performance liquid chromatography with ultraviolet detection and its application to a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852:174-179.
13. Lee CH, Yeh PH, Tsai TH. 2002. Hepatobiliary excretion of fluconazole and its interaction with cyclosporin A in rat blood and bile using microdialysis. Int. J. Pharm. 241:367-373.
14. Mauric O, et al. 2011. The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats. Pharmacology 87:130-134.
15. Muller M, De la Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453.
16. Pappas PG, et al. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
17. Pfaller MA, Pappas PG, Wingard JR. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 43(Suppl 1):S3-S14.
18. Romani L, Bistoni F, Puccetti P. 2003. Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts. Curr. Opin. Microbiol. 6:338-343.
19. Sasongko L, Williams KM, Day RO, McLachlan AJ. 2003. Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Br. J. Clin. Pharmacol. 56:551-561.
20. Sauermann R, et al. 2005. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob. Agents Chemother. 49:650-655.
21. Shargel L, Wu-Pong S, Yu ABC. 2005. Applied biopharmaceutics & pharmacokinetics, p 52-184. McGraw-Hill, New York, NY.
22. Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
23. Tasso L, Bettoni C, Oliveira L, Dalla Costa T. 2008. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. Int. J. Pharm. 358:96-101.
24. Xavier F, et al. 2003. On-line determination of fluconazole in blood and dermal rat microdialysates by microbore high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 787: 323-331.
25. Yang H, Wang Q, Elmquist WF. 1996. Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis. Pharm. Res. 13:1570-1575.